Clinical trialPhase 2Recruiting
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 9 April 2026
- Expected end
- 1 October 2031
- Enrollment
- 60 participants
- Sites
- 1
- Primary outcomes
- Safety and adverse events (AEs)
- Sponsor
- Other
- Results posted
- No
- Last update
- 5 October 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
Primary Objectives * Cohort 1: To evaluate the safety and tolerability of BMS-986504 in combination with neoadjuvant/adjuvant chemotherapy and as maintenance therapy in participants with resectable/borderline resectable PDAC. Major pathological response (MPR) and incidence, severity and duration of pre- and post-operative complications (e.g. delay of surgery, inability to get surgery, type and rate of postoperative complications \[like pancreatic fistula\], rate of resection for borderline participants) will be evaluated. * Cohorts 2 and 3: To evaluate the safety, tolerability and efficacy of BMS-986504 in concomitant with SOC chemo and as maintenance therapy. Efficacy will be evaluated as disease control (PFS) at 6 months in participants with locally advanced (Cohort 2) and metastatic (Cohort 3) PDAC. Secondary Objectives • To evaluate 6-month overall response rate (ORR) and disease control rate (DCR) for Cohorts 1,2 and 3